Guggenheim Capital LLC lifted its holdings in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 150.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 114,389 shares of the biotechnology company’s stock after buying an additional 68,730 shares during the period. Guggenheim Capital LLC’s holdings in Momenta Pharmaceuticals were worth $1,595,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also bought and sold shares of MNTA. Tocqueville Asset Management L.P. lifted its stake in shares of Momenta Pharmaceuticals by 243.6% in the fourth quarter. Tocqueville Asset Management L.P. now owns 963,784 shares of the biotechnology company’s stock worth $13,445,000 after buying an additional 683,296 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Momenta Pharmaceuticals by 9.3% in the fourth quarter. Renaissance Technologies LLC now owns 1,583,000 shares of the biotechnology company’s stock worth $22,083,000 after buying an additional 134,500 shares in the last quarter. Sectoral Asset Management Inc lifted its stake in shares of Momenta Pharmaceuticals by 34.3% in the fourth quarter. Sectoral Asset Management Inc now owns 500,298 shares of the biotechnology company’s stock worth $6,979,000 after buying an additional 127,799 shares in the last quarter. Arizona State Retirement System lifted its stake in shares of Momenta Pharmaceuticals by 224.8% in the fourth quarter. Arizona State Retirement System now owns 128,388 shares of the biotechnology company’s stock worth $1,791,000 after buying an additional 88,854 shares in the last quarter. Finally, BlackRock Inc. lifted its stake in shares of Momenta Pharmaceuticals by 0.8% in the fourth quarter. BlackRock Inc. now owns 10,473,316 shares of the biotechnology company’s stock worth $146,105,000 after buying an additional 82,691 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.
In other Momenta Pharmaceuticals news, Director Elizabeth Stoner sold 7,714 shares of Momenta Pharmaceuticals stock in a transaction dated Thursday, April 12th. The shares were sold at an average price of $20.00, for a total transaction of $154,280.00. Following the transaction, the director now directly owns 29,378 shares of the company’s stock, valued at $587,560. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Scott M. Storer sold 3,972 shares of Momenta Pharmaceuticals stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $15.16, for a total transaction of $60,215.52. The disclosure for this sale can be found here. Insiders have sold 128,682 shares of company stock worth $2,265,236 over the last ninety days. 4.40% of the stock is owned by insiders.
Shares of MNTA stock opened at $20.45 on Friday. Momenta Pharmaceuticals, Inc. has a 12 month low of $11.85 and a 12 month high of $21.00. The stock has a market cap of $1,552.54, a price-to-earnings ratio of -17.04 and a beta of 1.64.
Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported $0.18 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.12. Momenta Pharmaceuticals had a negative net margin of 63.43% and a negative return on equity of 23.62%. The company had revenue of $64.60 million for the quarter, compared to the consensus estimate of $66.59 million. During the same period in the previous year, the firm earned $0.60 earnings per share. Momenta Pharmaceuticals’s quarterly revenue was up 88.9% compared to the same quarter last year. equities analysts predict that Momenta Pharmaceuticals, Inc. will post -1.27 EPS for the current fiscal year.
Momenta Pharmaceuticals Profile
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.
Want to see what other hedge funds are holding MNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.